Psychedelics have demonstrated significant progress, with promising data and increased interest from large companies, ...

In today’s Pharmaceutical Executive Daily, Novartis plans to eliminate 550 positions at a major Swiss site, the FDA authorizes the first gene therapy for adolescents and adults with spinal muscular ...

PE: How will FDA's Priority Review Program impact domestic manufacturing? Conrad: A company is not going to de novo set up a new US-based manufacturing site just for this voucher. They cost billions ...

Layoffs are looming in Switzerland as Novartis announces its plans to cut upwards of 550 full-time positions by the end of ...

Businesses want to be available to provide for employees and be competitive. They want workers to be able to go to the HR ...

In today’s Pharmaceutical Executive Daily, Novo Nordisk faces market pressure after a late-stage trial setback, Moderna takes ...

AI and computational modeling are reducing reliance on animal testing by simulating human biology, improving drug safety and ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

In today’s Pharmaceutical Executive Daily, learn how Tesaro is suing AnaptysBio over alleged contract breaches, Flagship ...

Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, continues his conversation about ...

Psychedelics have demonstrated significant progress, generating enthusiasm across the neuroscience industry and leading to ...

Amid the usual hustle before a big medical conference or industry trade show, editors are often buried under a flood of news ...